Trial no.:
|
PACTR201804003249274 |
Date of Approval:
|
25/03/2018 |
Trial Status:
|
Retrospective registration - This trial was registered after enrolment of the first participant |
|
TRIAL DESCRIPTION |
Public title
|
Terlipressin infusion for prevention of vasoplegic syndrome in patients treated with ARBs undergoing CABG |
Official scientific title |
Terlipressin infusion for prevention of vasoplegic syndrome in patients treated with angiotensin II receptor antagonist undergoing coronary artery bypass graft surgery: a randomized controlled study |
Brief summary describing the background
and objectives of the trial
|
Preoperative use of renin angiotensin system antagonists has been considered an independent risk factor for development of vasoplegic syndrome. The aim of this study was to demonstrate efficacy of prophylactic terlipressin infusion for prevention of vasoplegic syndrome in patients treated with angiotensin receptor blocker undergoing coronary artery bypass graft surgery. |
Type of trial |
RCT |
Acronym (If the trial has an acronym then please provide) |
|
Disease(s) or condition(s) being studied |
Circulatory System,vasoplegic syndrome, coronary artery bypass graft surgery |
Sub-Disease(s) or condition(s) being studied |
|
Purpose of the trial |
Prevention |
Anticipated trial start date |
01/11/2017 |
Actual trial start date |
01/11/2017 |
Anticipated date of last follow up |
28/02/2018 |
Actual Last follow-up date |
28/02/2018 |
Anticipated target sample size (number of participants) |
100 |
Actual target sample size (number of participants) |
100 |
Recruitment status |
Completed |
Publication URL |
https://asja.springeropen.com/articles/10.1186/s42077-020-0054-6 |
|